Dr. Daniel N. Silverman, M.D.
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
- Medicare participating
At a glance
- Medical school
- Loyola University of Chicago, Stritch School of Medicine (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 123
Licensed in Illinois since 2015, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: Loyola University of Chicago, Stritch School of Medicine
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
SC license 83820 -
Internal Medicine Physician
IL license 036.138369 (first issued 2015; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Musc Medical Center Charleston, SC
Medical groups
- University Medical Associates of the Medical University of South Carol (1,668 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 123
- Services billed
- 319
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 68 | 29 |
| Established patient office or other outpatient visit, 30-39 minutes | 47 | 38 |
| Established patient office or other outpatient visit, 40-54 minutes | 36 | 32 |
| New patient office or other outpatient visit, 60-74 minutes | 27 | 27 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jardiance (empagliflozin) Other prescribers in Charleston, SC | 157 |
| Spironolactone Other prescribers in Charleston, SC | 84 |
| Eliquis (apixaban) Other prescribers in Charleston, SC | 75 |
| Entresto (sacubitril/valsartan) Other prescribers in Charleston, SC | 67 |
| Furosemide Other prescribers in Charleston, SC | 59 |
| Bumetanide Other prescribers in Charleston, SC | 53 |
| Ozempic (semaglutide) Other prescribers in Charleston, SC | 38 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Charleston, SC | 35 |
| Torsemide Other prescribers in Charleston, SC | 33 |
| Metoprolol Succinate Other prescribers in Charleston, SC | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $131 in total to this clinician.
| Abbott Laboratories | $105 |
|---|---|
| Merck Sharp & Dohme LLC | $25.70 |
| Food and Beverage | $105 |
|---|---|
| Education | $25.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Sep 23, 2025 | Education in-kind | $25.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $344,252 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Hea…
Merck Sharp & Dohme LLC - A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserv…
Merck Sharp & Dohme LLC - LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.
Boston Scientific Corporation · Completed · NCT04790344
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.